CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

upadacitinib

Last Updated: June 2, 2021
Result type: Reports
Project Number: SR0685-000
Product Line: Reimbursement Review

Generic Name: upadacitinib

Brand Name: Rinvoq

Manufacturer: AbbVie

Therapeutic Area: atopic dermatitis

Indications: RINVOQ is indicated for the treatment of adults and adolescents 12 years and older with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. RINVOQ can be used with or without topical corticosteroids.​

Manufacturer Requested Reimbursement Criteria1: For the treatment of patients aged 12 years and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable and/or who are refractory to or ineligible for systemic immunosuppressant therapies (i.e., due to contraindications, intolerance, or need for long-term treatment).

Submission Type: Initial

NOC Status at Filing: Pre NOC

Project Status: Active

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open March 15, 2021
Call for patient/clinician input closed May 07, 2021
Clarification:

- Patient input submission received from the Canadian Skin Patient Alliance (CSPA) & Eczéma Québec and the Eczema Society of Canada

Submission received April 13, 2021
Submission accepted April 27, 2021
Review initiated April 28, 2021
Draft CADTH review report(s) provided to sponsor for comment July 20, 2021
Deadline for sponsors comments July 29, 2021
CADTH responses on draft review report(s) provided to sponsor September 10, 2021
Expert committee meeting (initial) September 22, 2021
Draft recommendation issued to sponsor October 04, 2021
To
October 06, 2021
Draft recommendation posted for stakeholder feedback -